Program
CD8-guided IL-2 Fusion Protein AZD6750
Its studies are mostly in Melanoma, led by AstraZeneca.
Furthest: phase 2, since Jul 16, 20251 company-led study, 1 open or runningNext primary completion: Oct 2, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Jul 16, 2025 | Jul 16, 2025 | Oct 2, 2029phase 2 · NCT07115043 |
- Named in AstraZeneca’s own pipeline as
AZD6750
, phase 1, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2025First study: phase 2 study in MelanomaFirst studyNCT07115043 · 120 planned · United States, Australia, Japan and more
Ahead
- Oct 2, 2029Primary completion: phase 2 study in MelanomaNCT07115043
TargetBeta
“A recombinant fusion protein comprised of two CD8 binding domains and two IL-2 mutein domains, with potential immunostimulating and antineoplastic activities. Upon administration, CD8-guided IL-2 fusion protein AZD6750 specifically targets and preferentially binds, with its CD8 binding domains, t…”NCIt, read by Claude
“A recombinant fusion protein comprised of two CD8 binding domains and two IL-2 mutein domains, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07115043Melanoma · United States, Australia, Japan and more | 2 | Recruiting | Oct 2, 2029 | 120 |
How it is read
Names in the registry
- “AZD6750”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.